Generic Dolutegravir has made effective HIV treatment accessible and affordable worldwide while maintaining the same quality as brand-name products.
What are Generic Medications?
Generic medications contain the same active ingredient, strength, dosage form, and route of administration as brand-name drugs.
Bioequivalence:
Generic Dolutegravir must demonstrate bioequivalence to the innovator product, meaning it delivers the same amount of active ingredient to the bloodstream.
Quality Standards:
WHO-prequalified generic Dolutegravir meets the same quality, safety, and efficacy standards as brand-name products.
Cost Savings:
Generic Dolutegravir costs significantly less than brand-name versions, making treatment accessible to more people globally.
Regulatory Approval:
Generic manufacturers must obtain approval from regulatory authorities by demonstrating quality, safety, and bioequivalence.
Manufacturing Standards:
WHO-GMP certified facilities ensure generic Dolutegravir is manufactured to international quality standards.
Clinical Outcomes:
Studies show equivalent clinical outcomes between generic and brand-name Dolutegravir in terms of viral suppression and safety.
Global Access:
Generic Dolutegravir has enabled treatment scale-up in low and middle-income countries, benefiting millions of people with HIV.
Generic vs Brand Dolutegravir
Summary: Understanding the equivalence, quality, and cost-effectiveness of generic Dolutegravir medications.
Tags:
Generic Dolutegravir
bioequivalence
medication cost
WHO prequalification